Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma

BACKGROUND: Despite recent advances in the treatment of aggressive lymphomas, a significant fraction of patients still succumbs to their disease. Thus, novel therapies are urgently needed. As the anti-CD20 antibody rituximab and the CD19-targeting antibody tafasitamab share distinct modes of actions...

Descripción completa

Detalles Bibliográficos
Autores principales: Patra-Kneuer, Maria, Chang, Gaomei, Xu, Wendan, Augsberger, Christian, Grau, Michael, Zapukhlyak, Myroslav, Ilieva, Kristina, Landgraf, Karin, Mangelberger-Eberl, Doris, Yousefi, Kasra, Berning, Philipp, Kurz, Katrin S., Ott, German, Klener, Pavel, Khandanpour, Cyrus, Horna, Pedro, Schanzer, Jürgen, Steidl, Stefan, Endell, Jan, Heitmüller, Christina, Lenz, Georg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433160/
https://www.ncbi.nlm.nih.gov/pubmed/37600821
http://dx.doi.org/10.3389/fimmu.2023.1220558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433160/
https://www.ncbi.nlm.nih.gov/pubmed/37600821
http://dx.doi.org/10.3389/fimmu.2023.1220558

Ejemplares similares